Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Accenture plc (ACN) vs Zoetis Inc (ZTS) Price & Performance

Accenture plcTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Accenture plc vs Zoetis Inc — how do they compare? Accenture plc trades at $179.86 (market cap $110.04B), while Zoetis Inc trades at $73.68 (market cap $31.14B). The key difference: Accenture plc is far larger — about 3.5× Zoetis Inc's market cap, and Accenture plc pays the higher dividend (3.63%). Which is the better fit depends on your goals.

ACNZTS
Market Cap
$110.04B$31.14B
Sector
TechnologyHealth
52-Week High
$288.54$156.76
52-Week Low
$124.41$71.91
Enterprise Value
$108.26B$38.70B
Dividend Yield
3.63%2.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Accenture plc

Accenture (ACN) trades at $178.25, up 1.44% with strong technical and fundamental momentum. The stock shows bullish technical signals with support at $174 and resistance at $181, while recent earnings consistently beat expectations with Q1 2026 EPS of $3.80 versus $3.70 expected. Revenue growth accelerated to $69.67 billion in 2025, with solid profitability margins and attractive valuation metrics including P/E of 14.36. Recent partnerships with TEPCO and AlphaSense highlight ongoing AI-driven business transformation initiatives.

Outlook remains positive with analyst consensus price target of $189.77 offering 6.5% upside potential. Key opportunities include continued AI adoption and margin expansion, while risks involve competitive pressures and potential economic slowdown affecting consulting demand. The strong buy rating consensus (66% of analysts) supports continued investor confidence in the company's growth trajectory.

Zoetis Inc

Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.

The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Accenture plc

Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.

Read more on ACN

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS